NCT00174343View on ClinicalTrials.gov

Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 30, 2001

Study Completion Date

September 30, 2006

Conditions
Breast Neoplasms
Interventions
DRUG

exemestane (Aromasin®)

Trial Locations (5)

Unknown

Pfizer Investigational Site, Bordeaux

Pfizer Investigational Site, Clermont-Ferrand

Pfizer Investigational Site, Montpellier

Pfizer Investigational Site, Poitiers

Pfizer Investigational Site, Saint-Cloud

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00174343 - Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients | Biotech Hunter | Biotech Hunter